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A synthetic peptide vaccine which protects dogs against challenge with virulent canine parvovirus is
described. The amino acid sequence used was discovered in previous studies on the immunogenic properties
of previously mapped antigenic sites and represents the amino-terminal region of viral protein VP2. As with
marker vaccines, it is possible to discriminate between vaccinated dogs that have not been exposed to the virus
and dogs that have been infected with the virus. The protective mechanism can be explained by a humoral
response against the peptide aided by T-cell epitopes contained in the carrier protein used for peptide coupling.
This is the first example of a synthetic peptide vaccine that induces protection in target animals.
Vaccines based on synthetic peptides would be safe and easy
to produce. They would circumvent the risks in handling and
spreading of the infectious agent inherent to conventional
vaccines, and they would offer advantages over biologically
produced vaccines, namely, reproducibility, exclusion of con-
taminating microorganisms, and stability. A considerable num-
ber of synthetic peptides which induce neutralizing antibodies
(4-6, 16, 23, 25, 41, 54, 55) and, to a variable extent, protection
in the natural host (14, 15, 20, 22, 26, 35, 38, 50, 52, 56) have
been described. However, none has yielded sufficient protec-
tion for application in a vaccination program. An important
reason for this is that viral domains prone to neutralization
behave as mutational hot spots, especially in RNA viruses (24,
53), with the small nonenveloped picornavirus foot-and-mouth
disease virus and the complex retrovirus human immunodefi-
ciency virus type 1 being extensively studied examples (9, 17,
21, 32). Although these data have led to the general belief that
it is unrealistic to try to develop useful peptide vaccines, it
remains theoretically possible that full protective responses
could be achieved if the amino acid sequences used were based
on parts of the viral particle that are not prone to mutation but
are vital for its survival. We report here the validity of this
assumption in canine parvovirus (CPV).
CPV is one of the autonomously replicating members of the
Parvoviridae family, which are small (25-nm-diameter), nonen-
veloped, single-stranded DNA viruses (51). The DNA se-
quences of CPV and its highly homologous host range variants
isolated from cats, minks, and raccoons appear to be conserved
under field conditions (>98% homology) (33, 36, 37, 42, 43).
The viral capsid is composed of 60 protein subunits, of which
about 10% are VP1 and the remainder are VP2 and VP3 in
variable proportions (12, 57). Proteins VP1 (748 amino acid
residues) and VP2 (584 amino acid residues) are derived from
the same gene by differential splicing, and VP3 is derived from
VP2 by proteolytic removal of about 20 amino acids from the
N terminus. Therefore, the entire amino acid sequences of
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VP2 and VP3 are contained within the C terminus of VP1
(summarized in reference 12). While the spatial structure of
most of the VP2 domain is known from X-ray diffraction
analyses, the spatial structure of the amino-terminal 37 resi-
dues remains unknown because of its disordered state (1, 57).
The amino acid sequences of this part of VP2 are completely
identical in all CPV isolates and host range variants from cats,
minks, and raccoons which have been analyzed (33, 37, 42, 43).
The role and dynamics of the N terminus of VP2 in parvovi-
ruses are subject to speculation. However, the domain is
important because of the following observations. (i) Virus
neutralization has been observed in vitro with a monoclonal
antibody directed against this site (30). (ii) It is immunogenic
in several animal species (27). (iii) It is involved in in vitro cell
entry after the virus has attached to the membrane of the host
cell (at least in the homologous parvovirus minute virus of
mice [58]). The peptide vaccine described here is directed
against a part of this site.
As with other parvoviruses, CPV replication is the most
deleterious in actively dividing tissues (36). For dogs that do
not have antibodies against the virus, the consequences of
infection, namely, myocarditis in puppies less than 10 weeks
old and severe enteritis later on, are devastating. Resistance
against the disease is controlled by humoral immunity (for a
review, see reference 36). We report here that in young dogs,
effective protection of all animals (nine individuals tested)
against canine parvovirus was obtained with a synthetic peptide
vaccine. The selection of the sequence was based on a previous
search for neutralization-inducing activity of synthetic peptides
in rabbits (26a). The protective effect was provided by the
antipeptide antibodies which appeared to be dependent on
T-cell epitopes present in the carrier protein. To our knowl-
edge, this is the first report of host protection induced by a
synthetic peptide vaccine which can comply with requirements
for practical application.
MATERIALS AND METHODS
Animals. New Zealand White rabbits were from Charles
River (Sulzfeld, Germany). Specified-pathogen-free (SPF) fe-
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male beagle dogs were obtained from Harlan CPB, Zeist, The
Netherlands.
Materials. 9-Fluorenylmethoxycarbonyl (Fmoc) amino
acids and 4-(2',4'-dimethoxyphenyl-Fmoc-aminomethyl)-phe-
noxy resin (hereafter called Rink resin) (47) were purchased
from Saxon Biochemicals (Hannover, Germany), benzotria-
zole-1-yl-oxy-tris-(pyrrolidino)phosphonium hexafluorophos-
phate (PyBOP) was from Novabiochem (Laufelfingen, Swit-
zerland), and m-maleimidobenzoic acid-N-hydroxysuccinimide
ester (MBS) was from Sigma (St. Louis, Mo.). Keyhole limpet
hemocyanin (KLH) in the crystalline form was from Calbio-
chem (La Jolla, Calif.), goat anti-dog immunoglobulin (Ig)
peroxidase conjugate was from Cappel (West Chester, Pa.),
and swine anti-rabbit Ig peroxidase and rabbit anti-mouse Ig
peroxidase conjugates were from DAKO (Glostrup, Den-
mark). QuilA was prepared as previously described (13).
Aluminium hydroxide gel was a gift from S. J. Barteling
(Institute for Animal Science and Health, Lelystad, The Neth-
erlands). Complete and incomplete Freund's adjuvant were
from Difco Laboratories (Detroit, Mich.). Other solvents and
reagents used were of analytical grade.
Virus and cells. CPV strain CPV-c/780916 used in an
enzyme-linked immunosorbent assay (ELISA) for anti-CPV
antibody detection was obtained from the American Type
Culture Collection (VR-953) and propagated on feline kidney
cells (CRFK) (ATCC CCL94) and purified as previously
described (27). Challenge virus (a gift from A. Fernandez,
University of Cordoba, Cordoba, Spain) was obtained by
extraction from the feces of a mongrel dog that died from
CPV infection. Virus was extracted with tissue culture
medium and then treated with chloroform by established
procedures (7). The extract was passed through a 0.22-,um-
pore-size filter under sterile conditions and stored at -20°C
until used.
Peptides. Two peptides, il15 and 7L15, with the partially
overlapping sequences MSDGAVQPDGGQPAV and QPDG
GQPAVRNERAT, respectively, were used in this study. They
were synthesized on Rink resin (0.1-mmol scale, 0.48 mil-
liequivalent/g). Couplings were carried out with Fmoc-amino
acids (3 equivalents) in the presence of PyBOP (3 equivalents),
N-hydroxybenzoltriazole (3 equivalents), and diisopropylethyl-
amine (6 equivalents). The procedures for synthesis and depro-
tection were based on established methods (11, 47). The
syntheses were performed either manually in glass vessels or
on an Applied Biosystems 430A synthesizer using Fastmoc
chemistry (19). Peptides were synthesized with a cysteine at the
amino terminus for coupling with KLH and with the N and C
termini in the acetylated and amidated forms, respectively, and
were analyzed by high-performance liquid chromatography on
a C18 reversed-phase column (150 by 4.6 mm; bead diameter,
5 ,um; Supelcosil LC-18-DB; Supelco) using photodiode array
detection. A linear gradient of methanol from 10 to 80%
(1%/min) in 0.1% trifluoroacetic acid in water at 30°C at a flow
rate of 1 ml/min was used. Peptides were purified on a C18
reversed-phase column (2 by 25 cm; Bischoff Prap 2025).
Methanol gradients with a rise of 1% methanol per min at a
flow rate of 10 ml/min in water and 0.1% (vol/vol) trifluoro-
acetic acid were used. Amino acid analysis was performed both
before and after purification according to the procedures for
Picotag (Waters, Milford, Mass.).
Conjugation of peptides. Coupling of purified peptides to
KLH was performed by standard procedures with MBS as a
linking agent (28). In the conjugation procedure, dialysis,
instead of gel filtration, was used. After attachment of the
linker to KLH, 1 mg of peptide was added per mg of KLH
(protein content was determined by amino acid analysis), and
the mixture was incubated overnight at room temperature. For
the vaccine, the conjugates were used in the nondialyzed form.
The efficiency of coupling was checked by amino acid analysis
of dialyzed aliquots for each peptide and varied between 80 to
300,ug of peptide per mg of KLH.
Vaccination and immunization. A mixture of two nondia-
lyzed KLH-peptide conjugates (peptides iL15 and 7L15, 1 mg
each was injected into dogs and rabbits. This mixture (0.6 ml)
plus 50,ug of QuilA was adsorbed to 1 g of aluminium
hydroxide gel (final volume, 1.6 ml). Two consecutive vaccina-
tion experiments were performed with 3 dogs in the first
experiment and 10 dogs in the second experiment (Table 1).
The animals received the preparations by subcutaneous injec-
tion on days 1 and 30. Control dogs received placebo prepa-
rations containing amounts of KLH, QuilA, and aluminium
hydroxide equivalent to those used for the vaccinated dogs. On
day 72, the animals were exposed to challenge with CPV on
their eyes, noses, and mouths (2.5 ml). The condition, eating
habits, and rectal temperatures of the dogs were monitored
weekly or, during the experimental infection, daily. Blood
samples for preparation of serum and peripheral blood mono-
nuclear cells (PBMC) were collected at various times before
and during vaccination and after challenge. For immunization
of rabbits as reference animals, the immunization cocktail
(total volume, 2 ml) consisted of the same mixture of KLH-
conjugated peptides iL15 and 7L15 as used in the dogs,
adsorbed to aluminium hydroxide plus QuilA, and was admin-
istered by subcutaneous and intramuscular routes. On day 42,
the animals received a second injection of the same cocktail.
Peptide ELISA for detection of peptide-specific antibodies
and PEPSCAN. For peptide ELISA, all incubations were
carried out with 100-,ul volumes in the wells of polystyrene
microtiter plates and washes were performed between each
step with 0.05% (wt/vol) Tween 80 in phosphate-buffered
saline (PBS). The wells of polystyrene plates (Greiner, 665101)
were coated with peptides overnight at 4°C at 10 ,ug/ml in 50
mM Na-carbonate solution, pH 9.6. For incubation with the
first antibody, rabbit or dog sera were diluted in incubation
buffer, which consisted of 4% (vol/vol) horse serum, 1%
(wt/vol) Tween 80, and 0.5 M NaCl in PBS, and incubated for
1 h at 25°C. The second antibody incubation was at 25°C with
anti-rabbit or anti-dog Ig peroxidase diluted 1/1,000 in incuba-
tion buffer. Color was developed with tetramethylbenzidine
and stopped after 20 min with H2SO4. A450 was measured.
Sera from dogs were tested with a PEPSCAN procedure as
previously described, using the same set of solid-phase non-
apeptides representing the entire 748 residues of VP1 (27).
ELISA for detection of CPV-specific antibodies. Two differ-
ent methods were used to detect CPV-specific antibodies: an
indirect and a competitive anti-CPV ELISA. For the indirect
anti-CPV ELISA, the wells of plates (Polysorb; Nunc, Ros-
kilde, Denmark) were coated with purified CPV at 1 ,ug/ml in
0.5 M Na-carbonate buffer (pH 9.6) overnight at 4°C. Washes
between consecutive steps were carried out with 0.05% (wt/
vol) Tween 20 in physiological saline (Tween-saline). Coated
plates were incubated for 2 h at 37°C with dog or rabbit sera
diluted in 2% (wt/vol) bovine serum albumin in Tween-saline.
After the plates were washed, they were further incubated with
anti-rabbit or anti-dog Ig peroxidase conjugate in 2% (wt/vol)
bovine serum albumin in Tween-saline for 1 h at ambient
temperature. Color was developed with 100 ,ul of o-phe-
nylenediamine (1 mg/ml) in a solution of 24.3 mM citric acid,
51.4 mM Na2HPO4, and 0.012% (vol/vol) H202 and within 30
min stopped by the addition of 50 ,ul of 1.5 M H2SO4. A495 was
measured.
Competitive anti-CPV ELISA was performed as previously
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described (46). In this assay, plates coated with CPV antigen
were incubated with a mixture of dog serum samples (at
different concentrations) and a constant amount of CPV-
specific monoclonal antibodies conjugated to horseradish per-
oxidase.
DAS ELISA for the detection of CPV antigen. The presence
of CPV antigen in fecal samples was investigated with double-
antibody sandwich (DAS) ELISA as previously described (46).
In vitro neutralization and hemagglutination inhibition
(HI). Neutralizing activity of sera was determined by assaying
the CRFK cell monolayer protection activity as previously
described (30). In neutralization blocking experiments, undi-
luted serum samples were incubated with an equal volume of
culture medium with or without peptides IL15 plus 7L15 (final
concentration of peptides was 100 ,uM [each]). The samples
were further diluted in series starting from a serum dilution of
1/40, mixed with 100 hemagglutination units of CPV, and
incubated for 2 h at 37°C. Finally, cells were inoculated with
these mixtures and incubated according to the standard mono-
layer protection protocol.
HI tests were performed with African green monkey (Cer-
copithecus aethiops) erythrocytes as previously described (46).
Proliferative assays for dog PBMC. Heparinized blood
samples were collected from dogs in the second vaccination
experiment. PBMC were isolated by sedimentation of blood
samples on Lymphoprep (Nycomed, Oslo, Norway). Except for
the PBMC obtained at the end of the experiment (90 days
postinfection [dpi]), the cells were kept frozen at - 135°C in
Iscove's modified Dulbecco's medium (IMDM) supplemented
with 20% heat-inactivated fetal calf serum and 10% methyl
sulfoxide. For proliferative assays, PBMC were thawed and
cultured in 96-well round-bottom culture microtiter plates with
105 cells per well in IMDM supplemented with penicillin (100
IU/ml), streptomycin (100 ,ug/ml), L-glutamine (2 mM), 3-mer-
captoethanol (2 x 102 mM), and 10% heat-inactivated SPF
dog sera (negative for CPV antibodies). In addition, fresh
autologous gamma-irradiated (with 3,000 rads) PBMC, iso-
lated at 90 dpi after immunization, were added as feeder cells
at a concentration of 1.5 x 106 cells per well. The vitality of
PBMC was checked by stimulation with the T-cell mitogen
concanavalin A (5 jig/ml), which consistently resulted in
stimulation indices of over 50 (not shown). Stimulation was
performed with synthetic peptides (5 jig/well), peptide-KLH
conjugate as used for vaccination of dogs (2.5 ,ug [each] of two
conjugates per well), KLH (5 ,ug/well), and purified CPV (0.3
i,g/well) inactivated with P-propiolactone. PBMC were cul-
tured for 6 days; to increase the proliferation activity of the
stimulated cells, on day 5, recombinant human interleukin-2 (2
U/well) (Boehringer, Mannheim, Germany) was added to
those cultures that were started from thawed cells. During the
last 16 h of culture, PBMC were pulse-labeled with 0.5 ,uCi of
[3H]thymidine per well, and cell-associated radioactivity was
counted. Results were obtained from triplicate assays and
expressed as stimulation indices which represent the ratio of
counts per minute of stimulated and control (medium only)
cultures.
RESULTS
Vaccine composition and vaccination. Two pentadecapep-
tides, iL15 and 7L15, with the overlapping sequences MSD
GAVQPDGGQPAV and QPDGGQPAVRNERAT, respec-
tively (see Materials and Methods), were included in the
vaccine. Their sequences represent the first 21 amino acids of
the amino terminus of the major capsid protein VP2 of CPV.
This choice was based on previous studies on epitope mapping
(27, 30) and subsequent immunization of rabbits with a set of
peptides to further delineate the functional core of antigenic
sites (26a). It was shown that these two peptides could be used
to induce antibodies with in vitro neutralizing capacity.
Young, age-matched, and SPF dogs were injected with one
dose of the vaccine on days 1 and 30 (Table 1). A vaccine dose
contained a mixture of 1 mg of peptide IL15 and 1 mg of
peptide 7L15, with each peptide separately conjugated to
KLH. On day 72, the animals were challenged with CPV by the
oronasal and ocular routes. Two similar but completely sepa-
rate vaccination experiments were performed, with newly
prepared and purified peptides. These two independent exper-
iments with 3 and 10 dogs, respectively, yielded similar results.
Course of antibody production by vaccination. In all vacci-
nated animals, antipeptide and anti-CPV antibody titers were
nearly maximal at 2 weeks after the first immunization, rose
marginally within the next 10 days after the booster injection,
and then gradually declined (Fig. la and b). Serum neutraliz-
ing activity in the first vaccination experiment, as measured by
monolayer protection test, also appeared within 2 weeks and
was maximal between weeks 3 and 6, but then the titers
dropped below the detection level in the remaining preinfec-
tion period (Fig. ic). In the second experiment, none of the
dogs developed detectable in vitro neutralizing activity before
challenge (not shown). The control dogs remained seronega-
tive until seroconversion 6 dpi (Fig. lb and c).
Protection against challenge. Experimental exposure with a
fecal CPV preparation led to severe infection of all four
control dogs (Table 1), while the vaccinated animals remained
clinically healthy. The clinical signs in the control dogs were
anorexia, weakness, diarrhea, and severe intestinal hemor-
rhage (blood in the stool), which are typical CPV manifesta-
tions (39). The results of histologic examinations of these dogs
were in accordance with parvovirus infection. Analysis of
extracts from the intestinal tract for the presence of CPV by
established procedures (45) showed that the infection was
caused by CPV and not by other agents (e.g., canine corona-
virus). Of the four control dogs, one died at 6 dpi, another died
the next day, and the remaining two were euthanized on the
same day to stop further suffering. No anti-CPV antibodies
could be detected in any of the serum samples of the control
dogs except from 6 dpi (Fig. 1). Massive excretion of CPV in
the feces of these dogs was observed at 4 and 5 dpi, while in
four of nine vaccinated dogs, only a very low level of CPV on
5 dpi was found (Fig. 2). Body temperatures were elevated in
all control dogs on 4 dpi (above the normal fluctuation
maximum of 39.6°C) and in five of nine vaccinated animals on
5 or 6 dpi. Although this is an indicator for CPV infection (39),
none of the dogs vaccinated with the peptide vaccine became
clinically ill or showed any sign of disease, including loss of
appetite. Therefore, the vaccine efficiently protects dogs
against infection with virulent CPV.
Neutralization blocking experiments. The induction of in
vitro neutralizing activity in both nonvaccinated and vaccinated
dogs shortly after challenge (6 to 10 dpi [Fig. 1]), suggested the
occurrence of an additional class of neutralizing antibodies
directed to epitopes other than the linear neutralization site in
the VP2 N terminus. This was confirmed with neutralizing
antisera of dogs from the first vaccination experiment by
preincubation with the peptides used for vaccination (Table 2).
Before challenge, neutralizing activity in sera from vaccinated
dogs could be completely blocked. However, after challenge,
no blocking by the peptides was observed.
T-cell proliferation. The protective effect of vaccination with
peptides conjugated to KLH raised the question about the
origin of T-cell epitopes mediating the humoral response. The
J. VIROL.















FIG. 1. Course of antibody production in dogs vaccinated with
synthetic peptides. The results are given for the three dogs from
experiment 1 of which one (dog 3) received a placebo (Table 1). (a)
Peptide ELISA for detection of antipeptide antibodies with either
peptide IL15 (closed symbols) or 7L15 (open symbols) as the coated
antigen; (b) indirect CPV ELISA for detection of anti-CPV antibodies;
(c) virus neutralization test based on in vitro monolayer protection.
Symbols: El, control dog (dog 3); A, vaccinated dog 1; 0, vaccinated
dog 2. The control dog in this experiment died 6 dpi. In each test, the
lowest dilution analyzed was 1/10. Titers in an ELISA were taken at
those serum dilutions which yielded absorption values four times the
blank (preimmunization serum) value. Panels a and b are representa-
tive for both vaccination experiments.
proliferative activity of PBMC in vaccinated animals was
assayed as [3H]thymidine incorporation at the following five
times: before vaccination, before challenge, and after infection
at 9, 30, and 90 dpi (Fig. 3). Before and after challenge, T-cell
activity was observed when KLH was present as the antigen,
either free or conjugated to the peptides. After challenge, CPV
antigen was also able to induce a T-cell response, but this was
only obvious from 30 dpi on (while antibody titers were already
elevated at 8 dpi [Fig. 1 and 3]). The peptides themselves did
not induce any proliferation.
Discrimination between vaccinated and infected animals.
Many viruses including CPV are able to agglutinate erythro-
cytes which are reported to have distinct receptors for such
viruses, albeit these receptors are not necessarily the same as
those involved in infection of target cells. Antisera against
these viruses are often capable of inhibiting hemagglutination
TABLE 1. Vaccination of dogs against canine parvovirus'
Expt Age (wk) at Injected No. of dogs protected/
1st injection material' no. of dogs injected
1 13 Vaccine 2/2
Placebo 0/1
2 15 Vaccine 7/7
Placebo 0/3
aTwo similar vaccination experiments were performed at different times with
newly prepared peptides. In the first experiment, three 13-week-old female dogs
were kept in separate cages and one of the dogs served as a control. In the second
experiment, 10 15-week-old animals (4 females and 6 males) were used, housed
in three groups and one group (one female and two males) served as a control
group.
" Each dose of the vaccine contained 1 mg each of peptides IL15 and 7-15; 80
to 300 ,ug of each peptide was covalently bound to KLH, as determined by amino
acid analysis (see also Materials and Methods).
activity (HI). In general, CPV neutralizing antibodies also have
HI activity, but one monoclonal anti-CPV antibody (3C9) with
a strong neutralizing effect does not. This antibody was shown
to bind to the sequence QPAVR within the 21 N-terminal
residues of VP2 (27). The neutralizing antipeptide antibodies
from vaccinated dogs taken before challenge did not have HI
activity (Table 3), and the neutralizing rabbit antipeptide sera
also did not have HI activity (not shown). The challenge with
virus induced HI activity from 6 dpi on in vaccinated dogs and
also control dogs. Thus, with an HI assay and ELISA (Table 3;
Fig. 1), it is possible to discriminate between animals which
had been vaccinated with the synthetic peptide vaccine and
were not exposed to the virus (positive only by ELISA) and
animals which had been infected (positive by both ELISA and
HI).
Sequence specificity of antibodies from vaccinated dogs.
Previously, a linear site (SDGAVQ at positions 2 to 7 of VP2)
was recognized by three (of six) serum samples from dogs
naturally infected with CPV when analyzed in a PEPSCAN on
solid-phase synthetic peptides (27). This group of serum
samples was later extended with 12 other serum samples from






FIG. 2. Viral excretion in dog feces in vaccination experiment with
synthetic peptides. Analysis of samples from experiment 1 (Table 1) is
shown. The analyses of experiment 2 exhibited exactly the same
features: three control animals had high fecal CPV content on day 4
(absorbance values above 2), while of the seven vaccinated animals,
five had no detectable excretion and two had low absorbance values
(0.13 and 0.32) on 5 dpi only. The presence of CPV antigen was
determined by DAS ELISA. Symbols are as defined in the legend to
Fig. 1.
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Dog I Dog 2 dog 3
+ - + - + _
Before immunization (day 0) < < < < < <
After 2nd vaccination (day 43) < 800 < 800 < <
After challenge (6-10 dpi) 800 800 1,600 1,600 800 800
Sera were taken from dogs in experiment 1 (Table 1).
"Values are given as titers of neutralization determined in monolayer
protection test. Symbols: + and - indicate incubation with and without peptides
IL15 plus 7L15, respectively (see also Materials and Methods); <, no detectable
neutralizing activity (the lowest dilution measured was 1/10).
bound to sequences in the N-terminal domain of VP2. These
results indicate that the domain is not an immunodominant
site on the virus. On the other hand, the sera from the dogs
vaccinated with the peptides, taken either before or after the
challenge, bound to the N-terminal domain at another site
(DGGQPAVR at positions 9 to 16 of VP2) (Fig. 4).
DISCUSSION
In this report the first synthetic peptide vaccine which yields
protection in the target animal is described. Protection in dogs
was obtained with two overlapping peptides representing the
21-residue-long N terminus of VP2 of canine parvovirus. The
TABLE 3. Differentiation between vaccinated and infected dogs"
Titer"
No. of days after HI" ELISA"
immunization _
Dog I Dog 2 Dog 3 Dog 1 Dog 2 Dog 3
Before challenge
0 < < < < < <
71 < < < 320 160 <
After challenge
82 4,096 4,096 4,096" 5,120 5,120 2,560'
96 4,096 2,048 10,240 10,240
' Sera from the first experiment with two vaccinated dogs (dogs 1 and 2) and
one control dog (dog 3) were taken on the indicated day. Challenge with virus
occurred on day 72.
" The results of the two immunochemical tests are expressed as titers. <, below
the detection level.
In the HI assay, the lowest dilution tested was 1/4. In experiment 2, HI
activity (titer of >16) also started to appear from 6 dpi on in all animals (not
shown).
" In the competitive CPV ELISA, the lowest serum dilution tested was 1/40.
These samples were taken at day 78 because dog 3 died at day 78 (6 dpi).
protection obtained in two different experiments was repro-
ducible and effective in all vaccinated individuals (nine of
nine), even though the CPV preparation used for challenge
infection was highly virulent, causing severe disease in all four
control animals which succumbed as a result of infection. The
reason for this success can probably be attributed to a combi-
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FIG. 3. Antibody titer and T-cell activity in dogs vaccinated with the peptide vaccine. Results were obtained in animals from experiment 2
(Table 1). (a to c) Antibody titers for peptide IL15 (a) peptide 7L15 (b), and CPV (c), as measured by an ELISA performed as described in the
legend to Fig. 1. (d to i) T-cell proliferation expressed as stimulation indices for cells incubated with KLH (d), KLH-peptide conjugate (equal
amounts of KLH-lL15 and KLH-7L15) (e), CPV antigen (f), peptide iL15 (g), peptide 7L15 (h), and a control peptide (representing sequence
positions 570 to 584 of VP2) (i). Stippled bars indicate samples taken after challenge. Experimental stages: A, before vaccination; B, 70 days after
vaccination; C, 9 dpi; D, 30 dpi; and E, 90 dpi. PBMC in stages A to D had been stored frozen, and cells in stage E were directly used after isolation.
For more details, see Materials and Methods.
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naturally infected vaccinated with
peptide
MS DGAVQ P DGGQPAVRNNE RAT
FIG. 4. Core of amino acid sequence of antigenic site bound by
antibodies in neutralizing sera from dogs vaccinated with the synthetic
vaccine and from previously described (27) naturally infected dogs.
The amino-terminal 21 residues of VP2 are outlined. Core sequences
mapped with PEPSCAN are boxed.
VP2 to which the antipeptide antibodies were directed is a
flexible site (57), which will allow induced fit during antibody
binding. (ii) The N-terminal domain of VP2 is of functional
importance for the virus (58). (iii) A limited proportion of the
approximately 50 VP2 N termini in the viral capsid are exposed
so that only one or a few antibody molecules per virion are
needed to neutralize the virus (10, 27). (iv) The N terminus of
VP2 is a conserved domain in the different isolates from dogs,
cats, minks, and raccoons (33, 37, 42, 43).
CPV contains more than one site for neutralization. With
murine monoclonal antibodies, several neutralization sites
have been localized on the viral surface (8, 27, 30, 37, 44). For
the target animals, there is now also evidence for the existence
of multiple neutralization sites on CPV, based on the blocking
studies with the neutralizing dog sera and peptides (Table 2).
The peptide used in this study does not appear to be part of an
immunodominant site. This leads us to speculate about the
potential of the vaccine for induction of immunity in the
presence of antivirus antibodies (see below).
After challenge, the vaccinated dogs undergo a subclinical
CPV infection, which is probably the result of very limited
abortive viral replication. This is based on the following
observations: seroconversion occurred within 10 dpi in HI and
neutralization blocking assays, body temperature was elevated
in a number of animals at 5 or 6 dpi, and some fecal samples
at 5 dpi contained a very low level of CPV antigen (Tables 2
and 3; Fig. 2 to 4). Such effects were expected. Animals
vaccinated with inactivated CPV excrete some virus after
challenge, even if they had already a low level of preexisting
anti-CPV antibodies (18). Even when compared with other
studies (2, 39), the challenge we used was extraordinarily
devastating for the SPF control animals. Nevertheless, vacci-
nated animals were fully protected against disease, which
proves the efficacy of this peptide vaccine.
The protection obtained in our experiments seems to be
mediated by antipeptide antibodies (i.e., directed against the N
terminus of VP2), while T-cell responses hardly play a role at
the time of infection. The T-cell epitopes involved appeared to
be localized not in the peptides but within the carrier protein
KLH. Thus, the protection of the dogs by vaccination with the
peptide vaccine must have proceeded through the humoral
immune system in accordance with other studies using anti-
bodies directed against whole CPV (34, 36, 39).
An advantage of the peptide vaccine described in this report
is the possibility of designing tests which discriminate between
vaccinated and infected animals. With the HI test, animals
which had been infected with virus could be distinguished from
vaccinated animals before experimental infection (Table 3).
Alternative tests could obviously be developed, as is evident
from the blocking experiments, in which antibody binding
could be inhibited by the peptides used for vaccination only in
the sera taken before seroconversion (Table 2). Such discrim-
inatory tests are useful in programs to eradicate pathogenic
viruses like that applied with the veterinary marker vaccine for
pseudorabies virus infection in swine (59). They can also be of
importance in the surveillance of the occurrence of a virus, for
which vaccination with peptides might become available.
Another advantage of the synthetic peptide vaccine over
classical vaccines is its potential to overcome the nonrespon-
siveness to vaccination in young animals that is caused by the
presence of small residual amounts of maternal antibodies
which neutralize the live attenuated viruses used in conven-
tional vaccines. Conventional vaccination against CPV in pup-
pies younger than 10 weeks of age does not guarantee protec-
tion because they have maternally derived antibodies (40),
which were raised against whole virus. If the antibodies against
the peptide antigens of CPV are not among the maternally
derived antibodies, the peptide vaccine would allow triggering
of the immune system in the neonate at a much earlier stage
than is possible under present conditions. Our PEPSCAN data
suggest that indeed among the antibodies directed against
whole virus in infected control animals, the antipeptide anti-
bodies are probably not present.
Our results show for the first time that a peptide vaccine is
just as efficacious as the classical vaccine prepared from whole
virus. The question arises whether this approach also applies to
other pathogens. Since CPV is a DNA virus, we speculate that
at least for those viruses with low mutation rates, the minimal
requirements for full protection might be less stringent than
for RNA viruses. Because of this and the high homology
between the host range variants of CPV, feline panleukopenia
virus, mink enteritis virus, and raccoon parvovirus, we expect
that cats, minks, and raccoons will be equally well protected
when given a similar peptide vaccine. Furthermore, it is likely
that this approach is applicable for other parvoviruses for
which vaccination is desirable such as porcine parvovirus and
human B19 parvovirus (3, 31). It was recently shown that a
recombinant B19 capsid peptide with the amino acid sequence
of the N terminus of VP2 also induced neutralizing antibodies
(48), indicating that this domain is a general site for neutral-
ization in autonomously replicating parvoviruses. The fact that
it is a synthetic peptide or recombinant B19 capsid peptide may
be of interest for vaccination of humans. If the properties of
flexibility and limited exposure provide clues for obtaining
protective antipeptide antibodies, other DNA viruses and
small nonenveloped viruses should receive renewed attention
for a similar approach in preparing a synthetic vaccine. There-
fore, it is important to know how the N terminus of VP2
functions during CPV infection and whether other viral enti-
ties share analogous domains which could be the subject for
vaccine development.
In conclusion, we have shown that the synthetic vaccine for
immunization of dogs against CPV is acceptable and feasible
as well, because it was very effective under unusually heavy
conditions of challenge.
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